Analysis of sugammadex on deep neuromuscular blockade recovery in patients undergoing laparoscopic radical gastrectomy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300072327

Enrollment

Unknown

Registered

2023-06-09

Start date

2023-06-01

Completion date

Unknown

Last updated

2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

S group:Sugammadex 2 mg/kg

N group:Neostigmine 0.03mg/kg

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.The patients who are going to undergo laparoscopic radical gastrectomy with general anesthesia. 2.Aged 18-65 years, BMI 18-28kg/?. 3. The American Association of Anesthesiologists (ASA) graded ?-?.

Exclusion criteria

Exclusion criteria: 1. There are serious dysfunctions of important organs such as the heart ?lungs?liver and kidneys. 2.Patients with neuromuscular disease. 3. Allergic to anesthetic ?rocuronium ?sugammadex or neostigmine. 4.Participate in other clinical trials or refuse to participate in this study.

Design outcomes

Primary

Measure	Time frame
Time of tracheal extubation;The recovery time of TOFr=0.9;PACU residence time;	—

Secondary

Measure	Time frame
Hemodynamic index;Postoperative pulmonary complications;Occurrence of hypoxemia;coagulation;Occurrence of adverse reactions;	—

Countries

China

Contacts

Public ContactTian Shouyuan

Shanxi Province Cancer Hospital

chinatsyjj@126.com+86 138 0340 1773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026